Show simple item record

dc.contributor.authorNörder, Miriam
dc.contributor.authorBecker, Pablo D
dc.contributor.authorDrexler, Ingo
dc.contributor.authorLink, Claudia
dc.contributor.authorErfle, Volker
dc.contributor.authorGuzmán, Carlos A
dc.date.accessioned2010-11-25T15:41:46Z
dc.date.available2010-11-25T15:41:46Z
dc.date.issued2010
dc.identifier.citationModified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model. 2010, 5 (6):e11400 PLoS ONEen
dc.identifier.issn1932-6203
dc.identifier.pmid20628596
dc.identifier.doi10.1371/journal.pone.0011400
dc.identifier.urihttp://hdl.handle.net/10033/116324
dc.description.abstractBACKGROUND: Modified vaccinia virus Ankara (MVA), a highly attenuated strain of vaccinia virus, has been used as vaccine delivery vector in preclinical and clinical studies against infectious diseases and malignancies. Here, we investigated whether an MVA which does not encode any antigen (Ag) could be exploited as adjuvant per se. METHODOLOGY/PRINCIPAL FINDINGS: We showed that dendritic cells infected in vitro with non-recombinant (nr) MVA expressed maturation and activation markers and were able to efficiently present exogenously pulsed Ag to T cells. In contrast to the dominant T helper (Th) 1 biased responses elicited against Ags produced by recombinant MVA vectors, the use of nrMVA as adjuvant for the co-administered soluble Ags resulted in a long lasting mixed Th1/Th2 responses. CONCLUSIONS/SIGNIFICANCE: These findings open new ways to potentiate and modulate the immune responses to vaccine Ags depending on whether they are co-administered with MVA or encoded by recombinant viruses.
dc.language.isoenen
dc.subject.meshAdjuvants, Immunologicen
dc.subject.meshAnimalsen
dc.subject.meshAntibody Formationen
dc.subject.meshAntigen Presentationen
dc.subject.meshAntigens, Viralen
dc.subject.meshCD8-Positive T-Lymphocytesen
dc.subject.meshDendritic Cellsen
dc.subject.meshFemaleen
dc.subject.meshImmunizationen
dc.subject.meshImmunoglobulin Gen
dc.subject.meshMiceen
dc.subject.meshMice, Inbred C57BLen
dc.subject.meshModels, Animalen
dc.subject.meshOvalbuminen
dc.subject.meshSafetyen
dc.subject.meshSolubilityen
dc.subject.meshVaccines, Attenuateden
dc.subject.meshVaccinia virusen
dc.subject.meshViral Vaccinesen
dc.titleModified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model.en
dc.typeArticleen
dc.contributor.departmentDepartment of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.en
dc.identifier.journalPloS oneen
refterms.dateFOA2018-06-13T07:28:16Z
html.description.abstractBACKGROUND: Modified vaccinia virus Ankara (MVA), a highly attenuated strain of vaccinia virus, has been used as vaccine delivery vector in preclinical and clinical studies against infectious diseases and malignancies. Here, we investigated whether an MVA which does not encode any antigen (Ag) could be exploited as adjuvant per se. METHODOLOGY/PRINCIPAL FINDINGS: We showed that dendritic cells infected in vitro with non-recombinant (nr) MVA expressed maturation and activation markers and were able to efficiently present exogenously pulsed Ag to T cells. In contrast to the dominant T helper (Th) 1 biased responses elicited against Ags produced by recombinant MVA vectors, the use of nrMVA as adjuvant for the co-administered soluble Ags resulted in a long lasting mixed Th1/Th2 responses. CONCLUSIONS/SIGNIFICANCE: These findings open new ways to potentiate and modulate the immune responses to vaccine Ags depending on whether they are co-administered with MVA or encoded by recombinant viruses.


Files in this item

Thumbnail
Name:
Nörder et al_final.pdf
Size:
999.8Kb
Format:
PDF
Description:
original Open Access Publication

This item appears in the following Collection(s)

Show simple item record